A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection.

Onco Targets Ther · 2014 · PMC4085307 · PMID 25061319

Europe PMC DOI

hedged sentence

0.0370

closest p · 0.7× alpha

0.0370

boldest claim

The sentences

a significant trendP =0.037actually significant

For both PFS and OS, there was a significant trend of bevacizumab being more effective when given early (ie, as first-line rather than as second- or later-line treatment; PFS P =0.037 and OS P <0.001).

also in 6,248 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.